HomeCompareIVMED vs MAIN

IVMED vs MAIN: Dividend Comparison 2026

IVMED yields 285714.29% · MAIN yields 6.91%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IVMED wins by $1.734986541242196e+31M in total portfolio value
10 years
IVMED
IVMED
● Live price
285714.29%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.734986541242196e+31M
Annual income
$17,337,928,197,276,910,000,000,000,000,000,000,000.00
Full IVMED calculator →
MAIN
Main Street Capital Corporation
● Live price
6.91%
Share price
$52.96
Annual div
$3.66
5Y div CAGR
72.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$42.89M
Annual income
$35,818,348.00
Full MAIN calculator →

Portfolio growth — IVMED vs MAIN

📍 IVMED pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIVMEDMAIN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IVMED + MAIN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IVMED pays
MAIN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IVMED
Annual income on $10K today (after 15% tax)
$24,285,714.29/yr
After 10yr DRIP, annual income (after tax)
$14,737,238,967,685,373,000,000,000,000,000,000,000.00/yr
MAIN
Annual income on $10K today (after 15% tax)
$587.42/yr
After 10yr DRIP, annual income (after tax)
$30,445,595.80/yr
At 15% tax rate, IVMED beats the other by $14,737,238,967,685,373,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IVMED + MAIN for your $10,000?

IVMED: 50%MAIN: 50%
100% MAIN50/50100% IVMED
Portfolio after 10yr
$8.67493270621098e+30M
Annual income
$8,668,964,098,638,455,000,000,000,000,000,000,000.00/yr
Blended yield
99.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MAIN right now

IVMED
No analyst data
Altman Z
-205.3
Piotroski
2/9
MAIN
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$65.25
+23.2% upside vs current
Range: $60.00 — $70.00
Altman Z
1.7
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IVMED buys
0
MAIN buys
0
No recent congressional trades found for IVMED or MAIN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIVMEDMAIN
Forward yield285714.29%6.91%
Annual dividend / share$2.00$3.66
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%72.7%
Portfolio after 10y$1.734986541242196e+31M$42.89M
Annual income after 10y$17,337,928,197,276,910,000,000,000,000,000,000,000.00$35,818,348.00
Total dividends collected$1.734908400352195e+31M$41.85M
Payment frequencyquarterlymonthly
SectorStockBDC

Year-by-year: IVMED vs MAIN ($10,000, DRIP)

YearIVMED PortfolioIVMED Income/yrMAIN PortfolioMAIN Income/yrGap
1← crossover$28,582,129$28,571,428.57$12,434$1,193.51+$28.57MIVMED
2$76,351,353,429$76,320,770,551.21$16,255$2,280.05+$76351.34MIVMED
3$190,619,493,207,524$190,537,797,259,355.30$22,851$4,580.08+$190619493.18MIVMED
4$444,781,927,427,195,200$444,577,964,569,463,100.00$35,577$9,892.59+$444781927427.16MIVMED
5$969,967,353,346,567,200,000$969,491,436,684,220,000,000.00$63,653$23,664.70+$969967353346567.13MIVMED
6$1,976,961,629,315,093,000,000,000$1,975,923,764,247,012,300,000,000.00$136,601$65,054.52+$1976961629315092992.00MIVMED
7$3,765,923,944,594,039,000,000,000,000$3,763,808,595,650,671,000,000,000,000.00$368,044$214,504.02+$3.765923944594039e+21MIVMED
8$6,704,681,437,057,684,000,000,000,000,000$6,700,651,898,436,968,000,000,000,000,000.00$1,301,668$887,987.40+$6.704681437057683e+24MIVMED
9$11,156,275,836,497,016,000,000,000,000,000,000$11,149,101,827,359,364,000,000,000,000,000,000.00$6,288,483$4,825,407.47+$1.1156275836497015e+28MIVMED
10$17,349,865,412,421,960,000,000,000,000,000,000,000$17,337,928,197,276,910,000,000,000,000,000,000,000.00$42,886,603$35,818,348.00+$1.734986541242196e+31MIVMED

IVMED vs MAIN: Complete Analysis 2026

IVMEDStock

Whitebeard Inc., a development stage company, engages in the research and development of medical devices with `near-patient' testing applications. Its primary product includes prothrombin monitor, which is used for the measurement of coagulation of blood in patients at risk of heart disease and stroke. The company's other products under development include predictor of labor onset, a consumer device for maternity planning; biomarker monitor for the measurement of a number of biomarkers, including heart attack, HIV, cholesterol, and cancer; blood glucose monitor, a noninvasive glucose concentration continuous bulk measuring device measurement; digital scanning machine, a noninvasive alternative to 2D X-ray scanning; osteoporosis detection and monitoring device, an instant display of bonemineral density for osteoporosis patients; and hand held digital strip reader for immunoassay applications. It was formerly known as In Vivo Medical Diagnostics, Inc. and changed its name to In Veritas Medical Diagnostics, Inc. in 2005. The company is based in Inverness, the United Kingdom.

Full IVMED Calculator →

MAINBDC

Main Street Capital Corporation is a business development company specializes in equity capital to lower middle market companies. The firm specializing in recapitalizations, management buyouts, refinancing, family estate planning, management buyouts, refinancing, industry consolidation, mature, later stage emerging growth. The firm also provides debt capital to middle market companies for acquisitions, management buyouts, growth financings, recapitalizations and refinancing. The firm seeks to partner with entrepreneurs, business owners and management teams and generally provides one stop financing alternatives within its lower middle market portfolio. It prefers to invest in air freight and logistics, auto components, building products, chemicals, commercial services, computers, construction and engineering, consumer finance, consumer services, electronic equipment, energy equipment and services, financial services, health care equipment, health care providers, hotels, restaurants, and leisure, internet software and services, IT Services, machinery, oil, gas and consumable fuels, paper and forest products, professional and industrial services, road and rail, software, specialty retail, telecommunication, consumer discretionary, energy, materials, technology, and transportation. The firm typically invests in lower middle market companies generally with annual revenues between $5 million and $300 million. It prefers to invest in ranging between $2 million and $75 million in equity investment and enterprise value in ranging between $3 million and $20 million. The firm typically prefers to invest in the range of $5 million and $50 million per transaction in debt investment value and in the range of $1 million and $20 million in annual EBITDA. The firm's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies. It takes 5 percent minority and up to 50 percent majority equity investments. Main Street Capital Corporation was founded in 2007 and is based in Houston, Texas with an additional office in Chojnów, Poland.

Full MAIN Calculator →
📬

Get this IVMED vs MAIN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IVMED vs SCHDIVMED vs JEPIIVMED vs OIVMED vs KOIVMED vs ARCCIVMED vs HTGCIVMED vs GBDCIVMED vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.